Search results
Showing 1 to 9 of 9 results for duloxetine
In development [GID-TA11376] Expected publication date: 25 June 2025
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
and cost effectiveness of antiepileptics and antidepressants (other than duloxetine) for people with osteoarthritis? - What is the...
Osteoarthritis in over 16s: diagnosis and management (NG226)
This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Interim methods guide for developing good practice guidance (PMG15)
Interim methods guide for developing good practice guidance
and cost effectiveness of antiepileptics and antidepressants (other than duloxetine) for people with osteoarthritis? - What is the...